Sulfuric acid magnesium salt (1:1) → 7-[(3aS,4R,6R,6aR)-6-({[(3-{[6-chloro-5-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl]methyl}cyclobutyl)methyl](propan-2-yl)amino]methyl)-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine

HRID 511627ノート

反応式

HRID 511627 の反応式
[Cl:1][C:2]1[C:3]([C:26]([F:29])([F:28])[F:27])=[CH:4][C:5]2[N:9]=[C:8]([CH2:10][CH:11]3[CH2:14][CH:13]([CH:15]=O)[CH2:12]3)[N:7]([CH2:17][O:18][CH2:19][CH2:20][Si:21]([CH3:24])([CH3:23])[CH3:22])[C:6]=2[CH:25]=1.[CH3:30][C:31]1([CH3:54])[O:35][C@@H:34]2[C@@H:36]([CH2:49][NH:50][CH:51]([CH3:53])[CH3:52])[CH2:37][C@@H:38]([N:39]3[C:43]4[N:44]=[CH:45][N:46]=[C:47]([NH2:48])[C:42]=4[CH:41]=[CH:40]3)[C@@H:33]2[O:32]1.[O-]S([O-])(=O)=O.[Mg+2].C([O-])(O)=O.[Na+]>ClCCCl.[Cl-].[Na+].O>[Cl:1][C:2]1[C:3]([C:26]([F:29])([F:27])[F:28])=[CH:4][C:5]2[N:9]=[C:8]([CH2:10][CH:11]3[CH2:12][CH:13]([CH2:15][N:50]([CH2:49][C@@H:36]4[C@H:34]5[O:35][C:31]([CH3:54])([CH3:30])[O:32][C@H:33]5[C@H:38]([N:39]5[C:43]6[N:44]=[CH:45][N:46]=[C:47]([NH2:48])[C:42]=6[CH:41]=[CH:40]5)[CH2:37]4)[CH:51]([CH3:52])[CH3:53])[CH2:14]3)[N:7]([CH2:17][O:18][CH2:19][CH2:20][Si:21]([CH3:24])([CH3:22])[CH3:23])[C:6]=2[CH:25]=1

参加物

7

実験手順

A solution of 3-{[6-chloro-5-(trifluoromethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-1,3-benzodiazol-2-yl]methyl}cyclobutane-1-carbaldehyde (223 mg, 0.50 mmol), 7-[(3aS,4R,6R,6aR)-2,2-dimethyl-6-[(propan-2-ylamino)methyl]-hexahydrocyclopenta[d][1,3]dioxol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (172 mg, 0.50 mmol) and MgSO4 (600 mg, 5.00 mmol) in DCE (10 ml) was stirred for 15 min. STAB (148 mg, 0.70 mmol) was then added to the reaction mixture and stirred for 1 h at RT. The reaction was monitored by LCMS, no amine was seen after 2.5 h. Sat. NaHCO3 (20 ml) was added to the reaction mixture and stirred for 5 mins. Brine (20 ml) was then added to the reaction mixture. The product was extracted with DCM (2×30 ml), dried over Na2SO4, filtered and evaporated. Purification by prep. HPLC gave the desired product (174 mg, 45%) as a white solid; MS (ESI+) for C38H53ClF3N7O3Si m/z 776.30 [M+H]+; HPLC purity 100% (ret. time, 1.68 min); 1H NMR (500 MHz, MeOD) δH ppm −0.25-0.11 (9H, m), 0.90 (2H, td, J=7.88, 3.47 Hz), 1.30 (3H, s), 1.37 (6H, t, J=7.49 Hz), 1.55 (3H, s), 1.63-1.84 (1H, m), 1.99-2.37 (2H, m), 2.37-3.03 (6H, m), 3.04-3.28 (3H, m), 3.34-3.50 (1H, m), 3.61 (2H, td, J=7.92, 2.29 Hz), 3.79 (1H, br. s.), 4.68 (1H, t, J=6.70 Hz), 4.95-5.27 (2H, m), 5.55-5.81 (1H, m), 6.88 (1H, d, J=3.63 Hz), 7.06-7.62 (2H, m), 7.61-7.94 (1H, m), 7.94-8.16 (1H, m), 8.22 (1H, s)

後処理

  1. additionSTAB (148 mg, 0.70 mmol) was then added to the reaction mixture
  2. stirringstirred for 5 mins
  3. extractionThe product was extracted with DCM (2×30 ml)
  4. dry with materialdried over Na2SO4
  5. filtrationfiltered
  6. customevaporated
  7. customPurification by prep

出典と根拠

ORDレコード
ord-6e9fa54457ab4bbd95016904395fe86d
出典データセット
uspto-grants-2015_08
特許番号
US09096634B2

反応ノート

読み込み中…